Member Info for RayPointer

Has anyone else noticed that occasionally one of notpotalot's or pater's posts get a very big number of recs. I recall one of pater's posts getting 36 recs. Then suddenly most of the recs disappeared. Most strange.

The last one to get this inexplicable number of recs was notpotalots's post late yesterday evening.

He was having a go at viera and gets 22 recs. I don't know, perhaps viera has 22 ex-wives 😂

Pater, you seem to be very close to the CEO, seemingly knowing every thought in his head.

A bit like myself and rats 😂

Looks like AI generated rubbish to me.

"The stock currently trades at a 39% discount to our quantitative fair value estimate of 0.00 GBP per share; "

there could be a big market for ***s infused with sc134.

i novel new method of delivery and paid for by the patient 😂

VD, you seem to forget that we have 2 pre-clinical deals with Genmab

Flattery will get you nowhere, but maybe Flaherty will!

It does seem strange, to say the least, that a biotech on the verge of a deal with a major pharma should decide to change direction.

Unusually quiet here today for a share that's about to make us all "minted" 😂

VD

"Researchers at Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme (GBM)."

I'm thinking that Scancell will bring all these Immunobody offshoots back in-house.

We might already be seeing this with SCIB3 and SCIB4 now on the latest set of slides

Also there was a SCIB for glioblastoma multiforme at one time.

https://drug.russellpublishing.co.uk/news/12097/scancell-glioblastoma-multiforme/

VD, I think the results speak for themselves. Phil is obviously very busy selling our wares but we simply will not know the outcome of his efforts until the RNS lands.

Best case scenario, Phil is conducting an auction right now.

Ask Phil 🤣

Excellent post Marcus.

Scancell know all this, and so do we.

The market just hasn't woken up to how brilliant the science is.

Saint Jude has suddenly acquired more than 30 disciples. Very strange.

It's true that Scancell will use HLA type as part of eligibility for the Phase 3 trial. This is because iSCIB1+ has little of no affect on certain HLA types.

However, this is not an indication on how well a particular selected patient will respond.

I first bought Scancell shares in the late 19th century. That's me, bottom left.

https://www.lookandlearn.com/history-images/preview/M/M416/M416721_Scene-in-the-Stock-Exchange-1899.jpg

"Wait for the Scancell update. Anything else is just guesswork."

Very true C11.

This is the analogy that more and more applies to Scancell.

The heat is applied by the brilliant science and greatly enhanced by improving data to back it up.

When will the pressure cooking blow? Who knows.

All IMHO.

Temp ramp should positively welcome negative posts.

It gives the opportunity to buy more shares on the cheap when transformational news is certain in the very near future.